| INTRODUC TI ON
Acetaminophen (N-acetyl-para-aminophenol, paracetamol) is one of the most frequently used analgesic and antipyretic medications worldwide and is believed to act mainly through inhibition of cyclooxygenase enzyme and reduce prostaglandin synthesis. 1 It is a non-prescription medication and is available as a single entity product, or as a compound formula, for example, with other flu medications. Because of its popularity and accessibility, acute intentional and chronic unintentional acetaminophen overdoses are relatively common. However, given the lack of symptoms, or relative non-specificity of symptoms in the initial phase, acetaminophen poisoning is difficult to diagnose solely based on clinical findings. Without prompt diagnosis and treatment, those patients would, later on, develop severe hepatotoxicity and mortality may result. Because of the relatively high prevalence of acetaminophen poisoning in general population, non-specificity of early presenting signs and symptoms, and the significant yet preventable toxicity of acetaminophen, routine checking of serum acetaminophen in every patient presenting with a known intentional self-harm, suicidal attempts, or suspected intentional or unintentional overdose are recommended. Therefore, an efficient and reliable round-the-clock emergency service for serum acetaminophen quantitative testing should be available in every major hospital in view of the urgency in identifying and treating such patients.
The automated acetaminophen assays used by clinical laboratories can be broadly divided into two groups: the commonly used enzymatic assays and newer immunoassay-based assays.
The enzymatic assays have advantages of convenient and rapid compared to chromatographic methods, and being more economical compared to immunoassay-based assays. However, their performance is limited by different interfering substances such as bilirubin and hemoglobin in patient samples. 4 The immunoassay-based assays are generally less affected by bilirubin, hemoglobin, and also NAC interferences. program was unsatisfactory with high bias, alternate method with better analytical performance was sought for the analyzer. Various market available reagent kits of both enzymatic and immunoassaybased assays were explored, and five adoptable assay kits were selected for this study.
With the opportunity and resources to study five commercial assay kits simultaneously from independent researchers, this study provides objective and comprehensive information for the laboratory to select the most suitable method for acetaminophen determination on existing chemistry autoanalyzer. 
| MATERIAL AND ME THODS

| Linearity
A control blank serum sample was spiked with standard a solution of 
| High-dose hook effect
Control blank serums were further spiked with acetaminophen to yield final acetaminophen concentration of 18 000 µmol/L, which was then measured with the two immunoassay-based assays to look for the presence of possible high-dose hook effect.
| Interference studies
Common interferences such as lipemia, hemolysis, bilirubinemia, and NAC were included in this part of study. Variations from non-spiked sample by interference spiked sample within the RCPA APS (±20 up to 200 µmol/L or 10% if >200 µmol/L) were regarded as acceptable value without significantly affected by specific interfering substance.
| Lipemia
Control blank serums were spiked with acetaminophen and differ- 
| Hemolysis
Control blank serums were spiked with acetaminophen and different volumes of own preparation of red blood cell lysate, yielding final acetaminophen concentration of 100 µmol/L and hemoglobin concentrations of 0, 2, 4, 6, and 10 g/L, which were then measured with the five acetaminophen assays.
| Bilirubinemia
Control blank serum and sera of jaundiced patients with I-index
(173-341 µmol/L), and 4+ (342-684 µmol/L) were included for this experiment. Each of these samples was spiked with acetaminophen to final concentrations of 0, 100, and 1000 µmol/L and assayed.
Bilirubin interference is most concerned in enzymatic acetaminophen assays and was repeatedly reported in the literature. 4, 6, 7 Two concerns of bilirubin interference, the yellow pigment affecting absorption at near the same wavelength (around 600 nm) and the reduction property, may have different effects at low and high acetaminophen concentrations. Therefore, checking bilirubinemia for different acetaminophen concentrations was performed in this study.
| NAC interference (at low and high acetaminophen concentrations)
Control blank serums were spiked with acetaminophen and Hidonac 
| Interference due to sample matrix
Copper sulfate was used for color development in Beckman Coulter AU Paracetamol assay. Proteins in the sample may participate in the reaction and hence cause the matrix interference. To evaluate the possible interference due to sample matrix in the AU assay, samples with various concentrations of total protein from patients without exposure to acetaminophen were measured by this assay.
| Recovery of acetaminophen after ultrafiltration
Elimination of bilirubin interference by ultrafiltration from sample prior to measuring acetaminophen with enzymatic assay was suggested in the literature. 4 The three quality control materials of low, medium, and high acetaminophen levels (Liquid Unassayed Multiqual, Bio-Rad Laboratories) were measured before and after ultrafiltration with NanoSep 10 K (MW) OMEGA sample filters (Gelman, Port Washington, NY, USA) at 14 000 g for 15 minutes according to the recommendations by manufacturer. Acetaminophen levels in the pre-and post-treatment samples were measured with the three enzymatic acetaminophen assays, and percentage of recovery was calculated and compared accordingly.
| RE SULTS
| Imprecision & accuracy
Results of within-run and between-run imprecision study of the five acetaminophen assays are summarized in Table 1 . The precision profile of each assay derived from this study showed comparable results to the claims by the corresponding manufacturers. In general, enzymatic methods (Beckman Coulter AU, Abbott and Sekisui) showed better within-run and between-run precision than the immunoassay-based methods (Beckman Coulter SYNCHRON and Siemens).
The results of the accuracy study are summarized in Table 1 and 
| Linearity
The results of the linearity study are summarized in Tables 1 Since the claimed lower limits of linearity of the AU and SYNCHRON assays were 99 and 66 µmol/L, respectively, the performance for such low concentration of acetaminophen is for reference only.
Like other therapeutic drugs, reference range is not applicable for acetaminophen. For clinical concern of acetaminophen overdose, modified Rumack-Matthew nomogram is often referred. 3 The measured acetaminophen concentration and hours after ingestion should be correlated and considered for the treatment of patient with overdose of this drug.
| High-dose hook effect
The responses for serial dilutions measured by both immunoassaybased assays were linear, and no high-dose hook effect was demonstrated for both assays up to 18 000 µmol/L. This concentration is unlikely to be encountered in practical situations but can be served as information for the robustness of recent immunoassay-based assays eliminating such phenomenon.
| Interference study
| Lipemic interference
The results of lipemic interference study of the five acetaminophen assays are summarized in 
| Hemolysis interference
The results of hemolytic interference study of the five acetaminophen assays are summarized in Table 3 . The two immunoassaybased assays were virtually free from hemolytic interference despite the positive bias in Beckman Counter SYNCHRON assay. There was no significant interference at hemoglobin level up to 2.0 g/L for the three enzymatic methods at acetaminophen level of 100 µmol/L; however, beyond this level, a dose-dependent positive interference was observed with more than 20 µmol/L difference from non-hemolysis sample, and all three assays were affected at a similar magnitude.
| Bilirubin interference
It is known that icteric samples would cause false-positive results in blank serum samples in some of the assays. Table 3 .
| NAC interference
Both immunoassay-based assays and the Sekisui assay were relatively unaffected by NAC. Both the Abbott assay and the Beckman
Coulter AU assay showed dose-dependent negative interference by the addition of NAC, at both high and low concentrations of acetaminophen. The magnitude of negative interference of NAC on acetaminophen measurement was most significant in the Abbott assay where twofold to tenfold decrease in measured acetaminophen level for sample spiked with 3.06-12.3 mmol/L NAC was observed. The results are summarized in Table 3 .
| Interference due to sample matrix
It was noted that Beckman Coulter SYNCHRON and AU assays produced significantly higher acetaminophen results on blank samples 
| Recovery of acetaminophen after ultrafiltration
Enzymatic acetaminophen assays are prone to icteric interference, and ultrafiltration is considered one of the ways to eliminate such interference. Recovery of acetaminophen in the ultrafiltrate was estimated with the three enzymatic methods at acetaminophen levels of 99, 331, and 992 µmol/L. The Abbott and Sekisui assays showed superior performance (with recovery of 89.5% ± 3.0% and 88.0% ± 2.7%, respectively) to the Beckman Coulter AU assay (with 80.0% ± 5.1%). The results of post-ultrafiltration recovery are summarized in Table 4 .
| D ISCUSS I ON
In the current study, the analytical performances of the enzymatic acetaminophen assays are generally superior to the immunoassaybased assays in terms of precision, accuracy, and linearity ranges. 
Bilirubin causes interferences in acetaminophen measurements
with its broad and intense absorbance in the ultraviolet and visible regions of the electromagnetic spectrum, as well as the potential reactions with the reagents of the enzymatic assays by its metabolites or itself (ie, chemical interference). Among the three enzymatic assays evaluated in the study, the Abbott assay was most susceptible to icteric interference. The Beckman Coulter AU assay could tolerate mildly icteric sample, while in moderate-to-severe icteric samples positive interference at blank sample could be observed;
paradoxically, these levels of bilirubin would cause negative interference in samples containing acetaminophen. These false-positive or false-negative results could potentially lead to inappropriate treatment decisions in patient with exposure to acetaminophen or even misdiagnosis. Apart from the hemolytic and icteric interferences, the Abbott and Beckman Coulter AU assays (especially the former) were also subjected to significant negative interference in the presence of therapeutic concentrations of NAC.
To correct for bilirubin interference, mathematical correction based on the results obtained from samples spiked with unconjugated bilirubin was suggested but was not commonly used. 6 Ultrafiltration has been used in clinical laboratories for eliminating bilirubin interference. 4 In the current study, samples (with bilirubin concentration greater than which interference would occur) were subjected to ultrafiltration before acetaminophen measurement.
The Abbott assay demonstrated satisfactory recovery, while the Beckman Coulter AU assay had a generally lower recovery.
The Sekisui assay was demonstrated to have the best analytical performance among the three enzymatic assays, especially in interference studies. It was generally unaffected by NAC. Mild positive interference by total bilirubin was demonstrated in blank samples but not at higher acetaminophen levels. While the claimed limit of quantitation of 4 μmol/L could be verified in blank samples, there was significant icterus interference at low end of the analytical range, and thus, the lowest reporting limit should be set at a higher level (eg, 30 µmol/L), when such a level is still adequately low for clinical use.
In contrast to the enzymatic acetaminophen assays, the immunoassay-based assays are generally less susceptible to hemolytic, icteric, and NAC interferences, with also better reagent stability.
Among the two immunoassay-based assays, the Siemens SYVA Emit-tox Acetaminophen assay has the better performance in terms of accuracy, linearity, and tolerant to interference. The disadvantages include the slightly inferior performance in precision (and thus EQA performance), higher per-test cost, more calibration points required, and yet a narrower dynamic range. Mass spectrometric methods for acetaminophen measurement would have the highest specificity when free from common interference, 9 which may, however, be unsuitable for a 24-hour clinical emergency service.
In conclusion, among the five acetaminophen assays evaluated, all had satisfactory accuracy as reflected by EQA performance, except the Beckman Coulter SYNCHRON assay, in which bias and significant lipemic interference were both observed. The enzymatic assays overall had better analytical performances in terms of accuracy, precisions and linearity range: Both the Abbott and the Beckman Coulter AU assays were susceptible to hemolytic, icteric, and NAC interferences, which might be partially eliminated with sample ultrafiltration. The Sekisui assay shared the advantages of other enzymatic methods of being a simple, efficient, robust, and relatively inexpensive automated assay, which is more specific and less affected by the aforementioned interferences despite the icteric interference at low end. The Siemens assay is virtually free from bilirubin, hemoglobin, lipids, and NAC interferences, with a much lower limit of quantitation than the Sekisui assay, but still it may be susceptible to the disadvantages of an immunoassay-based method.
Different reagent manufacturers developed and launched their acetaminophen assays with modified formulations and advance technologies in the recent decade. Besides, improvement in analytical performance of automated chemistry analyzers is also expected. However, disappointing analytical performance of existing reagent on our analyzer was observed. With the opportunity seeking for alternatives and availability of resources, the study provides comprehensive and updated information on five selected commercial acetaminophen assays on our analytical platform.
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